207 related articles for article (PubMed ID: 37005129)
1. Rheumatological adverse events secondary to immune checkpoint inhibitors.
Garbarino MC; Manzano N; Messina O; Zylberman M
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):215-222. PubMed ID: 37005129
[TBL] [Abstract][Full Text] [Related]
2. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
[TBL] [Abstract][Full Text] [Related]
3. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.
Cappelli LC; Shah AA; Bingham CO
Rheum Dis Clin North Am; 2017 Feb; 43(1):65-78. PubMed ID: 27890174
[TBL] [Abstract][Full Text] [Related]
4. [Rheumatological complications of immune checkpoint inhibitor therapy].
Lazarou I; Fernandez E
Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253
[TBL] [Abstract][Full Text] [Related]
5. Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
Adileh M; Yuval JB; Huang S; Shoushtari AN; Quezada-Diaz F; Pappou EP; Weiser MR; Garcia-Aguilar J; Smith JJ; Paty PB; Nash GM
Dis Colon Rectum; 2021 May; 64(5):555-562. PubMed ID: 33939387
[TBL] [Abstract][Full Text] [Related]
6. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist.
Jamal S; Hudson M; Fifi-Mah A; Ye C
J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
[TBL] [Abstract][Full Text] [Related]
8. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
9. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Steven NM; Fisher BA
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
[TBL] [Abstract][Full Text] [Related]
10. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
Benesova K; Leipe J
Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268
[TBL] [Abstract][Full Text] [Related]
11. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
12. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
Gediz F; Kobak S
Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.
Greisen SR; Deleuran B
Curr Rheumatol Rep; 2021 Mar; 23(4):22. PubMed ID: 33651184
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M; Truchetet ME; Schaeverbeke T
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
[TBL] [Abstract][Full Text] [Related]
16. Toxicities from immunotherapy: From clinical trials to real-world clinical practice.
Riveiro-Barciela M; Trallero-Araguás E; Martínez-Valle F; ;
Med Clin (Barc); 2020 Dec; 155(12):541-547. PubMed ID: 32868034
[TBL] [Abstract][Full Text] [Related]
17. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy, Cancer and Rheumatological Diseases: A Review of the Literature and a Series of Cases in a University Hospital.
Nóvoa Medina FJ; Tejera Segura B; González Rodríguez E; Machín García S; Romero Díaz B; Rodríguez Abreu D
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):413-415. PubMed ID: 30471992
[TBL] [Abstract][Full Text] [Related]
19. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
Sebastiani GD; Scirocco C; Galeazzi M
Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
[TBL] [Abstract][Full Text] [Related]
20. Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review.
Juan-Carpena G; Palazón-Cabanes JC; Blanes-Martínez M
Actas Dermosifiliogr; 2022 Apr; 113(4):376-387. PubMed ID: 35623728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
